Skip to main content
Top
Published in: Journal of Translational Medicine 1/2023

Open Access 01-12-2023 | Research

Trajectory patterns of metabolic syndrome severity score and risk of type 2 diabetes

Authors: Atieh Amouzegar, Mohammadjavad Honarvar, Safdar Masoumi, Davood Khalili, Fereidoun Azizi, Ladan Mehran

Published in: Journal of Translational Medicine | Issue 1/2023

Login to get access

Abstract

Background

The available evidence indicates that the severity of metabolic syndrome tends to worsen progressively over time. We assessed the trajectory of age and sex-specific continuous MetS severity score (cMetS-S) and its association with the development of diabetes during an 18-year follow-up.

Methods

In a prospective population-based Tehran Lipid and Glucose Study, 3931 eligible participants free of diabetes, aged 20–60 years, were followed at three-year intervals. We examined the trajectories of cMetS-S over nine years using latent growth mixture modeling (LGMM) and subsequent risks of incident diabetes eight years later. The prospective association of identified trajectories with diabetes was examined using the Cox proportional hazard model adjusting for age, sex, education, and family history of diabetes, physical activity, obesity (BMI ≥ 30 kg/m2), antihypertensive and lipid-lowering medication, and baseline fasting plasma glucose in a stepwise manner.

Results

Among 3931 participants, three cMetS-S trajectory groups of low (24.1%), medium (46.8%), and high (29.1%) were identified during the exposure period. Participants in the medium and high cMetS-S trajectory classes had HRs of 2.44 (95% CI: 1.56–3.81) and 6.81 (95% CI: 4.07–10.01) for future diabetes in fully adjusted models, respectively. Normoglycemic individuals within the high cMetS-S class had an over seven-fold increased risk of diabetes (HR: 7.12; 95% CI: 6.05–12.52).

Conclusion

Although most adults exhibit an unhealthy metabolic score, its severity usually remains stable throughout adulthood over ten years of follow-up. The severity score of metabolic syndrome has the potential to be utilized as a comprehensive and easily measurable indicator of cardiometabolic dysfunction. It can be employed in clinical settings to detect and track individuals at a heightened risk of developing T2DM, even if their glucose levels are normal.
Appendix
Available only for authorised users
Literature
4.
go back to reference Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.CrossRefPubMed Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.CrossRefPubMed
5.
go back to reference Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23:786.CrossRefPubMedPubMedCentral Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23:786.CrossRefPubMedPubMedCentral
6.
go back to reference Ohnishi H, Saitoh S, Akasaka H, Furukawa T, Mori M, Miura T. Impact of longitudinal status change in metabolic syndrome defined by two different criteria on new onset of type 2 diabetes in a general Japanese population: the Tanno-Sobetsu Study. Diabetol Metab Syndr. 2016;8:64.CrossRefPubMedPubMedCentral Ohnishi H, Saitoh S, Akasaka H, Furukawa T, Mori M, Miura T. Impact of longitudinal status change in metabolic syndrome defined by two different criteria on new onset of type 2 diabetes in a general Japanese population: the Tanno-Sobetsu Study. Diabetol Metab Syndr. 2016;8:64.CrossRefPubMedPubMedCentral
7.
go back to reference Walden P, Jiang Q, Jackson EA, Oral EA, Weintraub MS, Rubenfire M. Assessing the incremental benefit of an extended duration lifestyle intervention for the components of the metabolic syndrome. Diabetes Metab Syndr Obes. 2016;9:177–84.CrossRefPubMedPubMedCentral Walden P, Jiang Q, Jackson EA, Oral EA, Weintraub MS, Rubenfire M. Assessing the incremental benefit of an extended duration lifestyle intervention for the components of the metabolic syndrome. Diabetes Metab Syndr Obes. 2016;9:177–84.CrossRefPubMedPubMedCentral
8.
go back to reference Low S, Khoo KCJ, Wang J, Irwan B, Sum CF, Subramaniam T, Lim SC, Wong TKM. Development of a metabolic syndrome severity score and its association with incident diabetes in an Asian population-results from a longitudinal cohort in Singapore. Endocrine. 2019;65:73–80.CrossRefPubMed Low S, Khoo KCJ, Wang J, Irwan B, Sum CF, Subramaniam T, Lim SC, Wong TKM. Development of a metabolic syndrome severity score and its association with incident diabetes in an Asian population-results from a longitudinal cohort in Singapore. Endocrine. 2019;65:73–80.CrossRefPubMed
9.
go back to reference Lee M-K, Han K, Kim MK, Koh ES, Kim ES, Nam GE, Kwon H-S. Changes in metabolic syndrome and its components and the risk of type 2 diabetes: a nationwide cohort study. Sci Rep. 2020;10:2313.CrossRefPubMedPubMedCentral Lee M-K, Han K, Kim MK, Koh ES, Kim ES, Nam GE, Kwon H-S. Changes in metabolic syndrome and its components and the risk of type 2 diabetes: a nationwide cohort study. Sci Rep. 2020;10:2313.CrossRefPubMedPubMedCentral
10.
go back to reference Huh JH, Ahn SG, Kim YI, Go T, Sung KC, Choi JH, Koh KK, Kim JY. Impact of longitudinal changes in metabolic syndrome status over 2 years on 10-year incident diabetes mellitus. Diabetes Metab J. 2019;43:530–8.CrossRefPubMedPubMedCentral Huh JH, Ahn SG, Kim YI, Go T, Sung KC, Choi JH, Koh KK, Kim JY. Impact of longitudinal changes in metabolic syndrome status over 2 years on 10-year incident diabetes mellitus. Diabetes Metab J. 2019;43:530–8.CrossRefPubMedPubMedCentral
11.
go back to reference Honarvar M, Masoumi S, Mehran L, Khalili D, Amouzegar A, Azizi F. Development and validation of a continuous metabolic syndrome severity score in the Tehran Lipid and Glucose Study. Sci Rep. 2023;13:7529.CrossRefPubMedPubMedCentral Honarvar M, Masoumi S, Mehran L, Khalili D, Amouzegar A, Azizi F. Development and validation of a continuous metabolic syndrome severity score in the Tehran Lipid and Glucose Study. Sci Rep. 2023;13:7529.CrossRefPubMedPubMedCentral
12.
go back to reference Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, Mehrabi Y, Zahedi-Asl S. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5.CrossRefPubMedPubMedCentral Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, Mehrabi Y, Zahedi-Asl S. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5.CrossRefPubMedPubMedCentral
13.
go back to reference Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8–13.CrossRefPubMed Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8–13.CrossRefPubMed
14.
go back to reference Hanley AJ, Karter AJ, Williams K, Festa A, D’Agostino RB Jr, Wagenknecht LE, Haffner SM. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation. 2005;112:3713–21.CrossRefPubMed Hanley AJ, Karter AJ, Williams K, Festa A, D’Agostino RB Jr, Wagenknecht LE, Haffner SM. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation. 2005;112:3713–21.CrossRefPubMed
15.
go back to reference Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48:1684–99.CrossRefPubMed Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48:1684–99.CrossRefPubMed
16.
go back to reference Ayubi E, Khalili D, Delpisheh A, Hadaegh F, Azizi F. Factor analysis of metabolic syndrome components and predicting type 2 diabetes: results of 10-year follow-up in a Middle Eastern population. J Diabetes. 2015;7:830–8.CrossRefPubMed Ayubi E, Khalili D, Delpisheh A, Hadaegh F, Azizi F. Factor analysis of metabolic syndrome components and predicting type 2 diabetes: results of 10-year follow-up in a Middle Eastern population. J Diabetes. 2015;7:830–8.CrossRefPubMed
17.
go back to reference Guo Y, Musani SK, Sims M, Pearson TA, DeBoer MD, Gurka MJ. Assessing the added predictive ability of a metabolic syndrome severity score in predicting incident cardiovascular disease and type 2 diabetes: the Atherosclerosis Risk in Communities Study and Jackson Heart Study. Diabetol Metab Syndr. 2018;10:42.CrossRefPubMedPubMedCentral Guo Y, Musani SK, Sims M, Pearson TA, DeBoer MD, Gurka MJ. Assessing the added predictive ability of a metabolic syndrome severity score in predicting incident cardiovascular disease and type 2 diabetes: the Atherosclerosis Risk in Communities Study and Jackson Heart Study. Diabetol Metab Syndr. 2018;10:42.CrossRefPubMedPubMedCentral
18.
go back to reference Gurka MJ, Golden SH, Musani SK, Sims M, Vishnu A, Guo Y, Cardel M, Pearson TA, DeBoer MD. Independent associations between a metabolic syndrome severity score and future diabetes by sex and race: the Atherosclerosis Risk In Communities Study and Jackson Heart Study. Diabetologia. 2017;60:1261–70.CrossRefPubMedPubMedCentral Gurka MJ, Golden SH, Musani SK, Sims M, Vishnu A, Guo Y, Cardel M, Pearson TA, DeBoer MD. Independent associations between a metabolic syndrome severity score and future diabetes by sex and race: the Atherosclerosis Risk In Communities Study and Jackson Heart Study. Diabetologia. 2017;60:1261–70.CrossRefPubMedPubMedCentral
19.
go back to reference Gurka MJ, Filipp SL, Pearson TA, DeBoer MD. Assessing baseline and temporal changes in cardiometabolic risk using metabolic syndrome severity and common risk scores. J Am Heart Assoc. 2018;7: e009754.CrossRefPubMedPubMedCentral Gurka MJ, Filipp SL, Pearson TA, DeBoer MD. Assessing baseline and temporal changes in cardiometabolic risk using metabolic syndrome severity and common risk scores. J Am Heart Assoc. 2018;7: e009754.CrossRefPubMedPubMedCentral
20.
go back to reference DeBoer MD, Gurka MJ, Woo JG, Morrison JA. Severity of the metabolic syndrome as a predictor of type 2 diabetes between childhood and adulthood: the Princeton Lipid Research Cohort Study. Diabetologia. 2015;58:2745–52.CrossRefPubMedPubMedCentral DeBoer MD, Gurka MJ, Woo JG, Morrison JA. Severity of the metabolic syndrome as a predictor of type 2 diabetes between childhood and adulthood: the Princeton Lipid Research Cohort Study. Diabetologia. 2015;58:2745–52.CrossRefPubMedPubMedCentral
21.
go back to reference Standards of care in diabetes-2023 abridged for primary care providers. Clin Diabetes 2022, 41:4–31. Standards of care in diabetes-2023 abridged for primary care providers. Clin Diabetes 2022, 41:4–31.
23.
go back to reference Khalili D, Asgari S, Lotfaliany M, Zafari N, Hadaegh F, Momenan AA, Nowroozpoor A, Hosseini-Esfahani F, Mirmiran P, Amiri P, Azizi F. Long-term effectiveness of a lifestyle intervention: a pragmatic community trial to prevent metabolic syndrome. Am J Prev Med. 2019;56:437–46.CrossRefPubMed Khalili D, Asgari S, Lotfaliany M, Zafari N, Hadaegh F, Momenan AA, Nowroozpoor A, Hosseini-Esfahani F, Mirmiran P, Amiri P, Azizi F. Long-term effectiveness of a lifestyle intervention: a pragmatic community trial to prevent metabolic syndrome. Am J Prev Med. 2019;56:437–46.CrossRefPubMed
24.
go back to reference Carleton RA, Lasater TM, Assaf AR, Feldman HA, McKinlay S. The Pawtucket Heart Health Program: community changes in cardiovascular risk factors and projected disease risk. Am J Public Health. 1995;85:777–85.CrossRefPubMedPubMedCentral Carleton RA, Lasater TM, Assaf AR, Feldman HA, McKinlay S. The Pawtucket Heart Health Program: community changes in cardiovascular risk factors and projected disease risk. Am J Public Health. 1995;85:777–85.CrossRefPubMedPubMedCentral
25.
go back to reference Luepker RV, Murray DM, Jacobs DR Jr, Mittelmark MB, Bracht N, Carlaw R, Crow R, Elmer P, Finnegan J, Folsom AR, et al. Community education for cardiovascular disease prevention: risk factor changes in the Minnesota Heart Health Program. Am J Public Health. 1994;84:1383–93.CrossRefPubMedPubMedCentral Luepker RV, Murray DM, Jacobs DR Jr, Mittelmark MB, Bracht N, Carlaw R, Crow R, Elmer P, Finnegan J, Folsom AR, et al. Community education for cardiovascular disease prevention: risk factor changes in the Minnesota Heart Health Program. Am J Public Health. 1994;84:1383–93.CrossRefPubMedPubMedCentral
26.
go back to reference Koohi F, Ahmadi N, Hadaegh F, Safiee S, Azizi F, Khalili D. Trajectories of cardiovascular disease risk and their association with the incidence of cardiovascular events over 18 years of follow-up: the Tehran Lipid and Glucose study. J Transl Med. 2021;19:309.CrossRefPubMedPubMedCentral Koohi F, Ahmadi N, Hadaegh F, Safiee S, Azizi F, Khalili D. Trajectories of cardiovascular disease risk and their association with the incidence of cardiovascular events over 18 years of follow-up: the Tehran Lipid and Glucose study. J Transl Med. 2021;19:309.CrossRefPubMedPubMedCentral
28.
go back to reference Meamar R, Amini M, Aminorroaya A, Nasri M, Abyar M, Feizi A. Severity of the metabolic syndrome as a predictor of prediabetes and type 2 diabetes in first degree relatives of type 2 diabetic patients: A 15-year prospective cohort study. World J Diabetes. 2020;11:202.CrossRefPubMedPubMedCentral Meamar R, Amini M, Aminorroaya A, Nasri M, Abyar M, Feizi A. Severity of the metabolic syndrome as a predictor of prediabetes and type 2 diabetes in first degree relatives of type 2 diabetic patients: A 15-year prospective cohort study. World J Diabetes. 2020;11:202.CrossRefPubMedPubMedCentral
29.
go back to reference Association AD: 15. Diabetes care in the hospital: standards of medical care in diabetes-2020. Diabetes Care 2020;43:S193-S202. Association AD: 15. Diabetes care in the hospital: standards of medical care in diabetes-2020. Diabetes Care 2020;43:S193-S202.
Metadata
Title
Trajectory patterns of metabolic syndrome severity score and risk of type 2 diabetes
Authors
Atieh Amouzegar
Mohammadjavad Honarvar
Safdar Masoumi
Davood Khalili
Fereidoun Azizi
Ladan Mehran
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2023
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-023-04639-w

Other articles of this Issue 1/2023

Journal of Translational Medicine 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine